Design Technician
Resume:
Curriculum Vitae
Paul Rayhorn
Protein Chemist/ Cell Biologist
********@*****.***
Home address:
Foxboro MA 02035
Professional Experience:
*/**** - */**** *****r Associate Scientist, Discovery Protein Chemistry
Dept. Biogen Idec, Inc. Cambridge MA
. Immunoassay design and implementation, especially ELISA, FRET, SPA
and other ligand-binding assays using novel mAbs and analytes,
typically interpolating unknowns by backfitting to a standard curve
with statistical evaluation using Excel, Sigmaplot, Deltagraph, or
Tablecurve software. I have created, developed, and optimized novel
immunoassays with unique antibodies and have written detailed
protocols for transfer to a development group.
. Monoclonal antibody characterization including isotyping, ranking
of large panels of mAbs by observed affinity, epitope mapping by
competitive inhibition, determination of kinetic binding values
with Biacore; colony selection of b-cell fusion hybridomas;
covalent labeling of antibodies with various flourescent dyes.
. Monoclonal antibody (and Ig-fusion) purification from hybridoma
supernatants - HPLC and gravity column chromatography, esp. Protein
A, Affinity, ion-exchange, SEC. I have used Waters, Akta, and
Agilent HPLC systems. Generation of detailed C of As, when
appropriate.
. Bioassays, including adhesion, proliferation, differentiation,
cytotoxicity, co-culture assays of both human and murine cell
lines using enzymatic/colorometric read-outs and H3-thymidine
incorporation as well as luminescent reporter gene expression. I
have grown lymphocytic, neuronal, and pluripotent cell lines and
have assayed for response to a variety of cytokines and mAbs, as
well as proliferation and mixed-lymphocyte reaction assays with
primary cell isolates.
. SDS-PAGE/Western blots (mostly Novex or Bio-rad minigels) with
radio-labeled proteins or chemiluminescent detection systems, as
well as 2D gels for proteomic and biomarker analysis. I am
proficient at resolving low-abundance proteins by WB.
. Peptide design (structure-based from molecular models), synthesis,
and purification; selection for use as antigens in hybridoma
production; peptide purification by RP-HPLC and conjugation of
peptides with Freund's Adjuvant.
. Mammalian Tissue Culture, care and feeding of established lines as
well as primary leukocyte cultures.
. FACS staining and evaluation of cell viability and surface-marker
expression, both single and multiple channels.
. Immunoprecipitation of low abundance proteins for phosphorylation-
state analysis
. PCR, mRNA isolation and amplification, transient transfection of
cell lines.
. Affinity purification of polyclonal rabbit sera
. Cellular fractionation, especially isolation of membranes and lipid
rafts.
1/96 - 5/97 Associate Scientist, Experimental Therapeutics
Ares Advanced Technology Randolph MA
. Bioassays, especially mixed-lymphocyte reaction assays with primary
cell isolates.
. Peptide synthesis (automated) and purification (reverse-phase).
. FACS staining and evaluation of cell viability and surface-marker
expression using BD FacScan and FacsCalibur.
. Mammalian Tissue Culture, care and feeding of established lines as
well as primary leukocyte cultures.
9/91-12/95 Technician, Structural Biology, Jefferson Cancer Center
Thomas Jefferson University Philadelphia, PA
. Peptide synthesis (automated) and purification (reverse-phase).
. Viral culture of HIV in BSL-3 facility.
. Peptide design (structure-based from molecular models).
Current employment:
2010 - present Investment Researcher, Biotechnology Consultant
Self-employed contractor
. Internet-based evaluation of biotech research pipelines for
potential investment by a private trust.
Education:
1987 - 1991 Marlboro College Marlboro VT
BS, Biochemistry (high honors)
Publications
1.Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor
progression in vivo by a transforming growth factor-beta-regulated
mechanism.
Van Aarsen LA, Leone DR, Ho S, Dolinski BM, McCoon PE, LePage DJ, Kelly R,
Heaney G, Rayhorn P, Reid C, Simon KJ, Horan GS, Tao N, Gardner HA, Skelly
MM, Gown AM, Thomas GJ, Weinreb PH, Fawell SE, Violette SM.
Cancer Res. 2008 Jan 15;68(2):561-70.
PMID: 18199553
2.Function-blocking integrin alphavbeta6 monoclonal antibodies: distinct
ligand-mimetic and nonligand-mimetic classes.
Weinreb PH, Simon KJ, Rayhorn P, Yang WJ, Leone DR, Dolinski BM, Pearse BR,
Yokota Y, Kawakatsu H, Atakilit A, Sheppard D, Violette SM.
J Biol Chem. 2004 Apr 23;279(17):17875-87. Epub 2004 Feb 11.
PMID: 14960589
3.Antibody blockade of the Cripto CFC domain suppresses tumor cell growth
in vivo.
Adkins HB, Bianco C, Schiffer SG, Rayhorn P, Zafari M, Cheung AE, Orozco O,
Olson D, De Luca A, Chen LL, Miatkowski K, Benjamin C, Normanno N, Williams
KP, Jarpe M, LePage D, Salomon D, Sanicola M.
J Clin Invest. 2003 Aug;112(4):575-87.
PMID: 12925698
4.Long-acting forms of Sonic hedgehog with improved pharmacokinetic and
pharmacodynamic properties are efficacious in a nerve injury model.
Pepinsky RB, Shapiro RI, Wang S, Chakraborty A, Gill A, Lepage DJ, Wen D,
Rayhorn P, Horan GS, Taylor FR, Garber EA, Galdes A, Engber TM.
J Pharm Sci. 2002 Feb;91(2):371-87.
PMID: 11835197
5.Comparative biological responses to human Sonic, Indian, and Desert
hedgehog.
Pathi S, Pagan-Westphal S, Baker DP, Garber EA, Rayhorn P, Bumcrot D, Tabin
CJ, Blake Pepinsky R, Williams KP.
Mech Dev. 2001 Aug;106(1-2):107-17.
PMID: 11472839
6.Enhanced potency of human Sonic hedgehog by hydrophobic modification.
Taylor FR, Wen D, Garber EA, Carmillo AN, Baker DP, Arduini RM, Williams
KP, Weinreb PH, Rayhorn P, Hronowski X, Whitty A, Day ES, Boriack-Sjodin A,
Shapiro RI, Galdes A, Pepinsky RB.
Biochemistry. 2001 Apr 10;40(14):4359-71.
PMID: 11284692
7.Mapping sonic hedgehog-receptor interactions by steric interference.
Pepinsky RB, Rayhorn P, Day ES, Dergay A, Williams KP, Galdes A, Taylor FR,
Boriack-Sjodin PA, Garber EA.
J Biol Chem. 2000 Apr 14;275(15):10995-1001.
PMID: 10753901
8.Regular articles: conditional disruption of hedgehog signaling pathway
defines its critical role in hair development and regeneration.
Wang LC, Liu ZY, Gambardella L, Delacour A, Shapiro R, Yang J, Sizing I,
Rayhorn P, Garber EA, Benjamin CD, Williams KP, Taylor FR, Barrandon Y,
Ling L, Burkly LC.
J Invest Dermatol. 2000 May;114(5):901-8.
PMID: 10771469
9.Functional antagonists of sonic hedgehog reveal the importance of the N
terminus for activity.
Williams KP, Rayhorn P, Chi-Rosso G, Garber EA, Strauch KL, Horan GS,
Reilly JO, Baker DP, Taylor FR, Koteliansky V, Pepinsky RB.
J Cell Sci. 1999 Dec;112 ( Pt 23):4405-14. Erratum in: J Cell Sci 1999
Dec;112(Pt 24):following 4800.
PMID: 10564658
10.Zinc-dependent structural stability of human Sonic hedgehog.
Day ES, Wen D, Garber EA, Hong J, Avedissian LS, Rayhorn P, Shen W, Zeng C,
Bailey VR, Reilly JO, Roden JA, Moore CB, Williams KP, Galdes A, Whitty A,
Baker DP.
Biochemistry. 1999 Nov 9;38(45):14868-80.
PMID: 10555969
11.Identification of a palmitic acid-modified form of human Sonic hedgehog.
Pepinsky RB, Zeng C, Wen D, Rayhorn P, Baker DP, Williams KP, Bixler SA,
Ambrose CM, Garber EA, Miatkowski K, Taylor FR, Wang EA, Galdes A.
J Biol Chem. 1998 May 29;273(22):14037-45.
PMID: 9593755
Patents:
U.S. application # PCT/US99/25700 Nov. 2,1999
Functional Antagonists of Hedgehog Activity
(co-inventor)
U.S. application # 60/286782 Apr. 26, 2001
Antibodies to the Ligand Binding Domain of Cripto
(co-inventor)
Contact this candidate